Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel

Purpose: To assess CA-125 in defining tumor response in patients treated with paclitaxel.

Patients and methods: We analyzed 150 women treated for epithelial ovarian carcinoma with platinum or paclitaxel. We compared the patients treated with two agents, using a precise definition of CA-125 response, determined by 50% and 75% reductions, like other authors have published.

Results: CA-125 criteria gave response rates very similar to the standard response rates, both for patients treated with platinum (75% vs 63%) and also for those treated with paclitaxel (40% vs 39%). Rates of false-positive prediction of response by CA-125 were also similar for patients treated with these two agents.

Conclusion: Precise 50% or 75% CA-125 response criteria are as sensitive as standard criteria for assessing activity of therapy for the ovarian cancers treated with platinum or paclitaxel. We propose that they may be useful in defining response in lieu of or in addition to standard response criteria in clinical trials involving epithelial ovarian cancer.

Paclitaxel; Platinum; CA-125; Ovarian cancer

[1] Rustin J.G., Marples M., Nelstrop A.E. et al.: "Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels". J. Clin. Oneal., 2001, 19, 4054.

[2] Fayers P.M., Rustin G., Wood R. et al.: "The prognostic value of serum CA-125 in patients with advanced ovarian carcinoma: An analysis of 573 patients by the Medical Research Council Working Party on Gynecological Cancer". Int. J. Gynaecol. Cancer, 1993, 3, 285.

[3] Miller A.B., Hoogstraten B., Staquet M. et al.: "Reporting results of cancer treatment". Cancer, 1981, 47, 207.

[4] Jacobs l.J., Rivera H., Oram D.H. et al.: "Differential diagnosis of ovarian cancer with tumour markers CA-125, CA-15-3 and TAG-72.3". Br. J. Obstet. Gynaecol., 1993, 100, 1120.

[5] Krebs H.B., Goplerud D.R., Kilpatrick S.J. et al.: "The role of CA- 125 as a tumour marker in ovarian cancer". Obstet. Gynecol., 1986, 67, 473.

[6] Rustin G.J., Nelstrop A.E., Tuxen M.K. et al.: "Definmg progression of ovarian carcinoma during follow-up according to CA-125: A North Thames Ovary Group Study". Ann. Oneal., 1996, 7, 361.

[7] Rustin G.J., Nelstrop A., Stilwell J. et al.: "Savings obtained by CA-125 measurements during therapy for ovarian carcinoma: The North Thames Ovary Group". Eur. J. Cancer, 1992, 28, 79.

[8] Rustin G.J.S.: "Use of CA-125 to assess response to new agents in ovarian cancer trial". J. Clin. Oneal., 2003, 15, 187.

[9] Rustin J.G., Nelstrop A.E., McClean P. et al.: "Defimng response of ovarian carcinoma to initial chemotherapy according to serum CA-125". J. Clin. Oncol., 1996, 14, 1545.

[10] Vergote I.B., Bormer O.P., Abeler V.M.: "Evaluation of serum CA- 125 levels in the monitoring of ovarian cancer". Am. J. Obstet. Gynecol., 1987, 157, 88.

[11] Altaras M.M., Goldberg G.L., Levin W. et al.: "The role of cancer antigen 125 (CA-125) in the management of ovarian epithelial carcinomas". Gynecol. Oncol., 1988, 30, 26.

[12] Guppy A.E., Rustin G.J.S.: "CA-125 response: can it replace the traditional response criteria in ovarian cancer?". Oncologist, 2002, 7, 437.

[13] Therasse P., Arbuck S.G., Eisenhauer E.A. et al.: "New guidelmes to evaluate the response to treatment in solid tumours". J. Natl. Cancer Inst., 2000, 92, 205.

[14] Vergote I., Rustin G.J.S., Eisenhauer E.A. et al.: "Reply to: New guidelines to evaluate the response to treatment in solid tumours (ovarian cancer)" (letter). J. Natl. Cancer Inst., 2000, 92, 1534.

[15] McIntosh M.W., Drescher C., Karlan B. et al.: "Combining CA- 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma". Gynecol. Oncol., 2004, 95, 9.

[16] Tarnrnela J., Lele S.: "New modalities in detection of recurrent ovarian cancer". Curr. Opin. Obstet. Gynecol., 2004, 16, 5.

[17] Maggino T. et al.: "Prospective rnulticenter study on CA-125 in postmenopausal pelvic masses". Gynecol. Oneal., 1994, 54, 117.

[18] Davelaar E.M., Bonfrer J.M., Verstraeten R.A. et al.: "CA-125: A valid marker in ovarian carcinoma patients treated with paclitaxel?". Cancer, 1996, 78, 118.

[19] Eisenhauer E.A., ten Bokkel Huinink W.W. et al.: "EuropeanCanadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion". J. Clin. Oncol., 1994, 12, 2654.

[20] Pearl M.L., Yashar C.M., Johnston C.M. et al.: "Exponential regression of CA-125 during salvage treatment of ovarian cancer with taxol". Gynecol. Oncol., 1994, 53, 339.

[21] Bridgewater J.A., Nelstrop A.E., Gordon J.S. et al.: "Companson of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel". J. Clin Oncol., 1999, 17, 501.

[22] lsonishi S.: "Biomarker in gynaecologic malignancies" (abstract) Gan To Kagaku Ryoho, 2004, 31, 1003.

[23] Jacobs l.J., Skates S., Davies A.P. et al.: "Risk of diagnosis of ovarian cancer after raised serum CA-125 concentration: a prospective cohort study". Br. Med. J., 1996, 313, 1355.

[24] Gore M.E., Cooke J.C., Wiltshaw E. et al.: "The impact of computed tomography and ultrasonography on the management of patients with carcinoma of the ovary". Br. J. Cancer, 1989, 60, 751.